GlassScriptPhysician profile
Dale Bryansmith
NPI 1639284052
$3,392.90
in general payments reported to CMS, 2019-2025
43 companies · $51.43 in 2025
The $51.43 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,606 · 2020: $681 · 2021: $38.74 · 2022: $16.14 · 2025: $51.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $51.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $51.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $332.90 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $286.72 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $212.56 | 2019-2025 | Imfinzi |
| Aurobindo Pharma USA, INC. | $196.74 | 2019-2020 | |
| Celgene Corporation | $195.63 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $158.84 | 2019-2020 | |
| Eisai INC. | $138.35 | 2019-2020 | |
| Genzyme Corporation | $136.37 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $130.03 | 2019 | |
| Amgen INC. | $123.63 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $113.10 | 2019-2020 | |
| Tesaro, INC. | $106.77 | 2019 | |
| Astellas Pharma US INC | $106.08 | 2019-2020 | |
| Pfizer INC. | $105.81 | 2019-2020 | |
| Lilly USA, LLC | $84.01 | 2019-2020 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dale Bryansmith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.